Evaluating Licensing Deals from the Board's Perspective
A licensing deal sits at an unusual intersection for a biopharma board. It is simultaneously a scientific decision, a financial transaction, a strategic commitment, and a signal to the market about how management values the company's own assets. Getting it wrong in any one dimension can undermine the value created in the others.
Yet boards regularly approach licensing discussions as though they were simply financial reviews — scrutinizing the headline economics while giving only passing attention to the strategic logic, the operational commitments, and the structural terms that will actually determine whether the deal delivers its promised value.
This article is a framework for boards that want to engage more substantively when management brings a licensing opportunity to the table.
Understanding What Kind of Deal You Are Actually Evaluating
Not all licensing deals are the same, and the board's role differs meaningfully depending on the structure.
An in-licensing deal — where the company acquires rights to a compound or technology from a third party — is primarily a resource allocation decision. The board is evaluating whether the asset is worth the capital and bandwidth commitment, whether it fits the strategic program, and whether management has the capability to develop it. The financial risk is real but bounded; the company is spending money it has (or will need to raise) on an asset with known characteristics.
An out-licensing deal — where the company grants rights to its own asset in exchange for upfront payments, milestones, and royalties — is a more complex governance matter. The board is evaluating not just the economics but whether the company is giving away the right asset at the right time to the right partner at the right price. The financial upside may be significant, but so is the opportunity cost if the asset is undervalued or if the licensee lacks the capability to fully realize it.
A co-development partnership — where both parties contribute resources and share the development risk and economics — introduces additional governance layers: joint steering committees, co-promotion rights, change-of-control provisions, and decision rights that may constrain the company's strategic flexibility for years.
The board should understand which structure it is evaluating before the financial discussion begins.
The Five Questions Every Board Should Ask
1. Why this partner, and why now?
This is the most important strategic question, and it is frequently the one that receives the least rigorous scrutiny. Management will have a view on the partner's capabilities, reputation, and strategic fit — but the board should probe that view rather than simply accept it.
What does this partner bring beyond capital? The best licensing relationships are ones where the partner adds capability the company cannot replicate on its own — a commercial infrastructure, a geographic footprint, a development organization with specific regulatory experience, an existing physician relationship network in the relevant indication. If the primary thing the partner brings is money, the board should ask whether there is a better way to raise that money.
Why now? The timing of an out-licensing deal is one of the highest-leverage decisions a clinical-stage company makes. Licensing an asset before Phase 2 data are available is fundamentally different from licensing it after a positive Phase 2 readout. The former preserves the company's capital at the cost of significant upside; the latter can generate substantially better economics at the cost of a longer wait. The board should understand what drove the timing decision and whether it was made proactively or reactively.
Is this the right partner for the asset's full potential? Large pharma partners offer commercial reach and development resources, but they also have broad portfolios and their own competing priorities. A smaller specialty pharma partner may be more focused but have more limited reach. The board should ask management to explain why this specific partner will maximize the probability that the asset reaches its full development and commercial potential — not just the probability that a deal gets done.
2. Does the economic structure reflect the asset's actual value?
The headline economics of a licensing deal — the upfront payment, the milestone schedule, the royalty rate — are the most visible elements of value, but they can obscure as much as they reveal.
Upfront payment is the only portion of deal value that is certain. Everything else is contingent. A deal with a large upfront and modest milestones may actually represent better risk-adjusted value than a deal with a small upfront and an ambitious milestone schedule that the licensee has limited incentive to hit. The board should understand what percentage of the total deal value is genuinely probable versus theoretically possible.
Milestone structure deserves scrutiny both in terms of amount and in terms of what triggers payment. Development milestones tied to IND submissions, Phase 1 completions, and first patient dosings are largely within the licensee's control. Regulatory and commercial milestones — approval, first commercial sale, revenue thresholds — depend heavily on factors neither party fully controls. The board should ask: what does the milestone schedule look like if the program experiences a one-year delay? A two-year delay? At what point does the licensee have a rational incentive to deprioritize or abandon the program?
Royalty rates matter, but they only matter if the product actually reaches market and achieves meaningful sales. A high royalty rate on an under-resourced development program is worth less than a lower royalty rate paired with a partner committed to maximizing commercialization.
3. What are we giving up?
Every licensing deal involves giving something up, and the board's job includes making sure that what is being given up is being valued appropriately.
Territory is the most obvious dimension. A global license to a best-in-class compound is a fundamentally different transaction than a territory-limited deal that preserves the company's rights in major markets. If the company is granting global rights, the board should understand why — and whether that decision forecloses meaningful strategic optionality.
Indication scope matters especially in oncology and immunology, where a compound may have relevance across multiple tumor types or disease settings. A license that grants broad indication rights may leave the company with nothing to offer a future acquirer.
Sublicensing rights determine whether the licensee can bring in additional partners — and take a spread on the economics in doing so — without the originating company's participation in the value created.
Change of control provisions are frequently overlooked until it is too late. If the licensee is acquired by a direct competitor, what happens to the licensed program? Many licensing agreements include change-of-control provisions that allow the licensor to terminate or renegotiate — but many do not, and the consequences can be significant.
4. What operational commitments is the company making?
Licensing deals do not always reduce the company's operational burden. Many deals — particularly co-development partnerships — require the company to contribute scientific resources, personnel, data, and management attention for extended periods. The board should understand exactly what the company is committing to operationally and whether it has the capacity to deliver.
Failure to meet the company's obligations under a licensing agreement can have significant legal and financial consequences. The board should ask: if key personnel leave, if funding becomes constrained, or if the scientific program takes an unexpected direction — can the company still meet its contractual commitments? And if not, what are the consequences?
5. How does this deal affect our exit options?
This question is rarely asked explicitly in licensing discussions, but it should be. Every out-licensing deal creates a new stakeholder whose interests will need to be managed in any future acquisition, IPO, or merger process. A licensing partner with broad rights, strong milestone economics, and change-of-control protections can complicate — and sometimes significantly reduce the value of — a future exit transaction.
The board should ask management and legal counsel to walk through what this deal looks like from the perspective of a potential acquirer. Does the licensing structure make the company more or less attractive? Are there provisions that would need to be unwound or renegotiated as part of an exit? Is the deal structure consistent with the company's stated long-term strategic objectives?
What Good Board Engagement Looks Like
The best licensing discussions I have observed in clinical-stage boardrooms share several characteristics.
Management comes prepared with more than financial models. They arrive with a clear articulation of the strategic rationale, a candid assessment of the partner's capabilities and limitations, a structured comparison of alternatives considered, and a frank analysis of what is being given up. The board's job is much harder when it is evaluating a deal in isolation rather than in the context of the choices management made to arrive at it.
The board has outside perspective. Where significant deals are concerned, it is entirely appropriate for the board to engage independent financial advisors or outside counsel to review the deal terms and provide a market-based assessment of whether the economics are consistent with comparable transactions. Management will always have an interest in completing the deal they have negotiated; the board's job is to evaluate it independently.
The conversation goes beyond the numbers. The board explores the strategic logic, the partner relationship, the operational commitments, and the exit implications — not just the IRR and the probability-weighted NPV.
And the board takes its time. A licensing deal that has taken months to negotiate can absorb another two weeks for proper board review. The urgency to close quickly is almost always less real than it appears, and the asymmetry of risk — the downside of closing a bad deal quickly vastly exceeds the downside of taking extra time to evaluate a good one — should inform the pace of the board's process.
A Final Note on Conflicts
Licensing discussions in venture-backed biopharma can create real conflicts of interest. A board member whose fund is also an investor in the proposed licensing partner, or who has a personal relationship with the partner's management team, should recuse themselves from the substantive discussion and the vote. A board member who is eager to generate a liquidity event — because the fund is nearing the end of its life, because the company's trajectory is uncertain, or for any other reason — may have an interest in closing a deal that is not fully aligned with the company's long-term value creation.
These conflicts are not unusual, but they need to be named and managed. The board's governance obligation is to the company's shareholders as a class — not to any individual stakeholder's preferred outcome.
Getting licensing governance right is ultimately about remembering that obligation and creating the conditions — rigorous process, independent judgment, honest analysis — that make it possible to honor it.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing and partnership transactions across pharmaceutical and advanced materials sectors.